Canterbury DHB


Mantle Cell Lymphoma (MCL)

In This Section



This presents problems as many patients are elderly and MCL often pursues a rapidly progressive course.

The outcome in this disease depends much more on the prognostic index of the MCL rather than any treatment selected.

See Martin, P. (2017). "Optimizing therapy for mantle cell lymphoma." Hematology Am Soc Hematol Educ Program 2017(1): 304-309.

Further Reading

Romaguera, J. E., L. E. Fayad, et al. (2010). "Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma." Br J Haematol 150(2): 200-8.

About this Canterbury DHB document (5958):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

December 2021

Next Review:

December 2024


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5958